Huperzine A for mild cognitive impairment

Yue, Jirong; Dong, Bi Rong; Lin, Xiufang; Yang, Ming; Wu, Hong; Wu, Taixiang

doi:10.1002/14651858.cd008827.pub2

Cited by 20 publications

(21 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, evidence suggests that these agents do not alter cognitive function outcomes or slow progression to dementia (Birks and Flicker, 2006; Farina et al, 2012; Russ, 2014; Yue et al, 2012). Thus, more recent efforts have focused on non-pharmacological interventions.…”

Section: Introductionmentioning

confidence: 99%

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

Rodakowski

Saghafi

Butters

et al. 2015

Molecular Aspects of Medicine

178

124

View full text Add to dashboard Cite

The purpose of this scoping review was to examine the science related to non-pharmacological interventions designed to slow decline for older adults with Mild Cognitive Impairment or early-stage dementia. We reviewed 32 unique randomized controlled trials that employed cognitive training (remediation or compensation approaches), physical exercise, or psychotherapeutic interventions that were published before November 2014. Evidence suggests that cognitive training focused on remediation and physical exercise interventions may promote small improvements in selected cognitive abilities. Cognitive training focused on compensation interventions and selected psychotherapeutic interventions may influence how cognitive changes impact daily living. However, confidence in these findings is limited due methodological limitations. To better assess the value of non-pharmacological interventions for this population, we recommend: 1) adoption of universal criteria for “early stage cognitive decline” among studies, 2) adherence to guidelines for the conceptualization, operationalization, and implementation of complex interventions, 3) consistent characterization of the impact of interventions on daily life, and 3) long-term follow-up of clinical outcomes to assess maintenance and meaningfulness of reported effects over time.

show abstract

Section: Introductionmentioning

confidence: 99%

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

Rodakowski

Saghafi

Butters

et al. 2015

Molecular Aspects of Medicine

178

124

View full text Add to dashboard Cite

show abstract

“…A number of plant-based interventions have been investigated for their effects on cognition and dementia including turmeric (Ahmed and Gilani, 2014), salvia species (Miroddi et al, 2014), Gingko biloba extract (Solfrizzi and Panza, 2015;Chan et al, 2015) and the plant-derived acetylcholinesterase inhibitor huperzine A (Yue et al, 2012;Yang et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

et al. 2016

View full text Add to dashboard Cite

Mild cognitive impairment (MCI) is a condition that may be prodromal to the development of dementia. There remain, as yet, no approved pharmaceutical interventions for MCI. Chinese herbal medicines (CHMs) have a long history of use for cognitive impairments and some plant ingredients have shown neuroprotective actions in experimental studies. This review assesses the current clinical evidence from controlled clinical trials for the effects of CHMs on cognitive outcomes as measured by Mini-mental state examination (MMSE) or Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog). Fifty one studies (4026 participants) were included. These compared CHM with placebo, supportive care, pharmaceutical treatment or combined CHM with a pharmaceutical in an integrative setting. For the eight randomised controlled trials (RCTs) of comparisons with placebo, MMSE was significantly higher in the CHM groups (MD 1.56 [0.78, 2.34] I = 85%, n = 503), similarly for eight RCTs of comparisons with supportive care (MD 1.77 [1.33, 2.21] I = 0%, n = 555). Benefits were also evident in comparisons with some pharmaceuticals and with integrative treatment. The small size of most studies and methodological weaknesses mean that these results should be interpreted with caution. Further studies employing rigorous methods are required to investigate the potential benefits of these CHMs for MCI. Copyright © 2016 John Wiley & Sons, Ltd.

show abstract

“…65 However, one trial demonstrated no signicant change in cognitive function as measured by Alzheimer's disease Assessment Scale-Cognitive Subscale (ADAS-Cog) 66 and clinical data are limited by poor methodological quality. 67 Pro-drug of huperzine A, named ZT-1, derived from natural product, is a potent and selective AChE inhibitor. The results from the Phase I clinical trials showed that ZT-1 has an admirable pharmacokinetic with a rapid absorption and a wide distribution in human.…”

Section: Cholinergic Drugsmentioning

confidence: 99%

Two decades of new drug discovery and development for Alzheimer's disease

et al. 2017

View full text Add to dashboard Cite

show abstract

Huperzine A for mild cognitive impairment

Abstract: Effectiveness of huperzine A, nimodipine and the combinative utilization to age associated memory impairment and influence of those to levels of plasma total antioxidant capacity and calcium of platelet [in Chinese].

Cited by 20 publications

References 53 publications

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: An updated scoping review

Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes

Two decades of new drug discovery and development for Alzheimer's disease

Contact Info

Product

Resources

About